A Randomized Clinical Trial of the Effect of Pimecrolimus Cream 1% Compared With Topical Corticosteroid in Treatment of Erosive Oral Lichen Planus
NCT ID: NCT01524744
Last Updated: 2012-02-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
40 participants
INTERVENTIONAL
2009-03-31
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment of Oral Erosive Lichen Planus With Pimecrolimus Cream
NCT00321750
Efficacy of Elidel Cream on Erosive Oral Lichen Planus
NCT00130572
Clinical and Immunohistochemical Effect of Topical Pimecrolimus in Treatment of Oral Lichen Planus
NCT02443311
Pimecrolimus Cream for Oral Lichen Planus
NCT00297037
Evaluation of Lycopene in the Treatment of Erosive Oral Lichen Planus
NCT04652739
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pimecrolimus ointment 0.1 %
This group used drugs 3 times a day for 2 months and then didn't eat or drink for 20 minutes after use
Pimecrolimus ointment
Case group used drugs 3 times a day for 2 months and then didn't eat or drink for 20 minutes after use
Adcortyl
triamcinolone acetonide 0.1% in orabase
Adcortyle
Control group used adcortyle (triamcinolone acetonide 0.1% in orabase, Bristol-Myers Squibbb, Anagn, Italy)
Adcortyl
triamcinolone acetonide 0.1% in orabase
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pimecrolimus ointment
Case group used drugs 3 times a day for 2 months and then didn't eat or drink for 20 minutes after use
Adcortyl
triamcinolone acetonide 0.1% in orabase
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Systemic diseases or malignancy
* Pregnancy
* Lesion/lesions with dysplasia/ history of allergic reaction to corticosteroids or immunomodulatory drugs.
* Lesions adjacent to amalgam filling were also excluded from this study.
8 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mashhad University of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
ATESSA PAKFETRAT
Associate professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
atessa pakfetrat, associate professor
Role: PRINCIPAL_INVESTIGATOR
Mashhad University of Medical Science
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mashhad University of Medical Science
Mashhad, Khorasan Razavi, Iran
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
87909
Identifier Type: OTHER
Identifier Source: secondary_id
87909
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.